UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Journal of the American Academy of Dermatology, 2017-08, Vol.77 (2), p.310-317.e1

2017

Volltextzugriff (PDF)

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

The Lancet (British edition), 2012-08, Vol.380 (9843), p.738-746

2012

Volltextzugriff (PDF)

Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis

American journal of clinical dermatology, 2014-12, Vol.15 (6), p.467-478

2014

Volltextzugriff (PDF)

Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study

Journal of sexual medicine, 2018-11, Vol.15 (11), p.1645-1652

2018

Volltextzugriff (PDF)

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)

JEADV clinical practice, 2023-06, Vol.2 (2), p.282-292

2023

Volltextzugriff (PDF)

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2022-05, Vol.158 (5), p.533

2022

Volltextzugriff (PDF)

AJC Editor's Consensus: Psoriasis and Coronary Artery Disease

The American journal of cardiology, 2008-12, Vol.102 (12), p.1631-1643

2008

Volltextzugriff (PDF)

Psoriasis in children and women: addressing some special needs

Seminars in cutaneous medicine and surgery, 2014-03, Vol.33 (2 Suppl 2), p.S42-S44

Cather, Jennifer C

2014

Volltextzugriff (PDF)

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies

Dermatology and therapy, 2016-12, Vol.6 (4), p.639-647

2016

Volltextzugriff (PDF)

33054 Improvement in touch avoidance in patients with genital psoriasis treated with ixekizumab: 52-week results of a phase 3 clinical trial in patients with moderate-to-severe genital psoriasis (IXORA-Q)

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB69-AB69

2022

Volltextzugriff (PDF)

The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients

Expert review of clinical immunology, 2011-01, Vol.7 (1), p.9-13

2011

Volltextzugriff (PDF)

Proceedings of the 5th Annual Perspectives in Rheumatic Diseases

Seminars in arthritis and rheumatism, 2013-12, Vol.43 (3), p.416-419

2013

Volltextzugriff (PDF)

The Editor’s Roundtable: Psoriasis, Inflammation, and Coronary Artery Disease

The American journal of cardiology, 2008-04, Vol.101 (8), p.1119-1126

2008

Volltextzugriff (PDF)

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2006, Vol.54 (1), p.61-63

2006

Volltextzugriff (PDF)

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

The Lancet (British edition), 2017-06, Vol.389 (10086), p.2287-2303

2017

Volltextzugriff (PDF)

Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.116-124

2008

Volltextzugriff (PDF)

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach

Journal of the American Academy of Dermatology, 2009-07, Vol.61 (1), p.S1-S46

2009

Volltextzugriff (PDF)

51214 Deucravacitinib efficacy in palmoplantar and fingernail psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA) in the phase 3 POETYK PSO-1 and PSO-2 trials

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB179-AB179

2024

Volltextzugriff (PDF)

51582 Simultaneous Genital Skin Clearance and Patient Reported Outcome Responses at Weeks 24 and 52 in Patients with Moderate-to-Severe Genital Psoriasis Treated with Ixekizumab: an analysis of the Phase 3 Clinical Trial IXORA-Q

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB310-AB310

2024

Volltextzugriff (PDF)

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

The New England journal of medicine, 2014-07, Vol.371 (4), p.326-338

2014

Volltextzugriff (PDF)

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis

Dermatology (Basel), 2006-01, Vol.213 (3), p.204-214

2006

Volltextzugriff (PDF)

25357 Malignancies related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB56-AB56

2021

Volltextzugriff (PDF)

52687 Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB144-AB144

2024

Volltextzugriff (PDF)

357 The effect of upadacitinib on the genital region in moderate-to-severe atopic dermatitis: an analysis from the Measure Up 1 and Measure Up 2 studies

British journal of dermatology (1951), 2023-01, Vol.188 (Supplement_2)

2023

Volltextzugriff (PDF)

Cannabidiol primer for healthcare professionals

Proceedings - Baylor University. Medical Center, 2020-07, Vol.33 (3), p.376-379

2020

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(121)

Publikationsform

Sprache

Englisch
(147)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis

Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial

AJC Editor's Consensus: Psoriasis and Coronary Artery Disease

Psoriasis in children and women: addressing some special needs

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies

33054 Improvement in touch avoidance in patients with genital psoriasis treated with ixekizumab: 52-week results of a phase 3 clinical trial in patients with moderate-to-severe genital psoriasis (IXORA-Q)

The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients

Proceedings of the 5th Annual Perspectives in Rheumatic Diseases

The Editor’s Roundtable: Psoriasis, Inflammation, and Coronary Artery Disease

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach

51214 Deucravacitinib efficacy in palmoplantar and fingernail psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA) in the phase 3 POETYK PSO-1 and PSO-2 trials

51582 Simultaneous Genital Skin Clearance and Patient Reported Outcome Responses at Weeks 24 and 52 in Patients with Moderate-to-Severe Genital Psoriasis Treated with Ixekizumab: an analysis of the Phase 3 Clinical Trial IXORA-Q

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis

25357 Malignancies related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

52687 Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis

357 The effect of upadacitinib on the genital region in moderate-to-severe atopic dermatitis: an analysis from the Measure Up 1 and Measure Up 2 studies

Cannabidiol primer for healthcare professionals

Suchergebnisse filtern